semaglutide salt lake city GLP-1 Weight Loss Solutions FDA Warns on Certain Forms
Description
Glepaglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Analogue, for Patients With Short Bowel Syndrome: A Randomised Phase 2 Trial
As GLP-1 agonist use rises, so do reports of adverse events
That is roughly 33 pounds for someone starting at 220 pounds
doi: 10.1371/journal.pone.0104873
Subsequent trials demonstrated cardiovascular benefits: in the SUSTAIN 6 trial, semaglutide reduced major adverse cardiovascular events by 26% in high-risk patients, a finding that led to FDA approval for cardiovascular risk reduction in January 2020
A.PetersonC.WinslowD.OdehS.GaddeK
